Metabolic and Cardiovascular Clinical Research
Precision where it matters most
Metabolic and cardiovascular conditions diabetes, obesity, and their downstream complications require clinical research that is as disciplined in execution as it is thoughtful in design. Long observation windows, comorbidities, adherence challenges, and the practical realities of sustained patient engagement all demand a CRO that thinks ahead, not just one that follows process.
At Southern Star Research, we support sponsors developing metabolic therapies by combining scientific rigour with operational judgement.
Our Medical Monitors have direct clinical experience giving our teams genuine therapeutic insight, not just procedural familiarity.
Indication experience
Our diabetic foot ulcer programme is currently initiating, targeting 120 patients across a regional hospital network – demonstrating our ability to design and execute studies beyond metropolitan site clusters.
Why Australia for metabolic and cardiovascular clinical trials?
Australia’s highly regulated research environment, experienced investigator network, and efficient clinical governance support reliable delivery across long-duration metabolic studies. Data meets FDA, EMA, and other major regulatory standards.
The R&D tax incentive scheme reduces development costs materially for sponsors operating under budget pressure – a meaningful advantage for the leaner biotech teams that bring us most of their early metabolic work.